Systematic review of economic evidence for the detection, diagnosis, treatment, and follow-up of colorectal cancer in the United Kingdom
暂无分享,去创建一个
Alan Brennan | Paul Tappenden | Jim Chilcott | Hazel Pilgrim | A. Brennan | P. Tappenden | J. Chilcott | H. Pilgrim
[1] P Tappenden,et al. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. , 2007, Health technology assessment.
[2] N Bosanquet,et al. Short-term costs of conventional vs laparoscopic assisted surgery in patients with colorectal cancer (MRC CLASICC trial) , 2006, British Journal of Cancer.
[3] W. Scheithauer,et al. Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial , 2006, British Journal of Cancer.
[4] J Chilcott,et al. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. , 2010, Health technology assessment.
[5] C. Carroll,et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. , 2007, European journal of cancer.
[6] P. Tappenden,et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. , 2008, Health technology assessment.
[7] D. Whynes,et al. Retesting positive results in screening for colorectal cancer: a marginal analysis , 1991 .
[8] P. Ewings,et al. Randomized clinical trial comparing laparoscopic and open surgery for colorectal cancer within an enhanced recovery programme , 2006, The British journal of surgery.
[9] S. Beard,et al. Hepatic Resection for Colorectal Liver Metastases: A Cost-Effectiveness Analysis , 2000, Annals of surgery.
[10] A. Williams,et al. Assessment of faecal occult blood loss by qualitative and quantitative methods. , 2002, Journal of the Royal College of Surgeons of Edinburgh.
[11] J. Almond,et al. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer , 2007, British Journal of Cancer.
[12] M. McKee,et al. Options for Screening for Colorectal Cancer in the Royal Air Force: A Cost-effectiveness Evaluation , 1995, Journal of the Royal Army Medical Corps.
[13] S. Paisley,et al. Cost-effectiveness of oxaliplatin and capecitabine in the adjuvant treatment of stage III colon cancer , 2006, British Journal of Cancer.
[14] J. Scholefield,et al. Risk‐stratified intensive follow up for treated colorectal cancer – realistic and cost saving? , 2008, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[15] R. Fitzpatrick,et al. Issues in methodological research: perspectives from researchers and commissioners. , 2001, Health technology assessment.
[16] Daniel R. Miller,et al. Final report , 2000 .
[17] David K Whynes,et al. Cost-Effectiveness of Screening for Colorectal Cancer: Evidence from the Nottingham Faecal Occult Blood Trial , 2004, Journal of medical screening.
[18] R. James,et al. New face for a familiar friend: the deGramont regimen in the treatment of metastatic colorectal cancer given as an outpatient: a feasibility study , 2002 .
[19] P. Ewings,et al. The influence of an Enhanced Recovery Programme on clinical outcomes, costs and quality of life after surgery for colorectal cancer , 2006, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[20] N. Freemantle,et al. Cost-effectiveness of oxaliplatin in combination with 5-FU/FA compared with 5-FU/FA alone , 2001 .
[21] A. Dhar,et al. National Institute for Health and Clinical Excellence , 2005 .
[22] A. Horgan,et al. Preoperative Intensive, Community-Based vs. Traditional Stoma Education: A Randomized, Controlled Trial , 2005, Diseases of the colon and rectum.
[23] J. Primrose,et al. Costs of neoadjuvant chemotherapy and surgery in patients with liver metastases from advanced colorectal cancer , 2001 .
[24] M. Deverill,et al. Systematic review and economic modelling of effectiveness and cost utility of surgical treatments for men with benign prostatic enlargement. , 2008, Health technology assessment.
[25] D. Kerr,et al. An economic comparison of the net clinical benefit and treatment costs of raltitrexed and 5-fluorouracil + leucovorin (Mayo regimen) in advanced colorectal cancer , 1999 .
[26] David K Whynes,et al. Cost effectiveness analysis of intensive versus conventional follow up after curative resection for colorectal cancer , 2004, BMJ : British Medical Journal.
[27] I. Durand-zaleski,et al. Cost‐effectiveness of systemic and regional chemotherapy for the treatment of patients with unresectable colorectal liver metastases , 1998, Cancer.
[28] D. Whynes,et al. Rehydration of guaiac-based faecal occult blood tests in mass screening for colorectal cancer. An economic perspective. , 1991, Scandinavian journal of gastroenterology.
[29] S. Maslekar,et al. Cost analysis of transanal endoscopic microsurgery for rectal tumours , 2007, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[30] H. Wasan,et al. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). , 2007, European journal of cancer.
[31] D. Whynes,et al. Cost savings in mass population screening for colorectal cancer resulting from the early detection and excision of adenomas. , 1992, Health economics.
[32] D. Whynes,et al. Is an immunological faecal occult blood test better than Haemoccult? A cost-benefit study. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[33] P. Tappenden,et al. Option appraisal of population-based colorectal cancer screening programmes in England , 2006, Gut.
[34] D. Whynes,et al. Cost-effective screening strategies for colorectal cancer. , 1992, Journal of public health medicine.
[35] R. Mihai,et al. Transanal endoscopic microsurgery--impact on the practice of a colorectal surgeon in a district general hospital. , 2005, Annals of the Royal College of Surgeons of England.
[36] K. D. Vellacott,et al. Flexible sigmoidoscopy in general practice , 2002, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.
[37] A. Horgan,et al. A prospective case-matched comparison of clinical and financial outcomes of open versus laparoscopic colorectal resection , 2007, Surgical Endoscopy.
[38] R. Newcombe,et al. Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging? , 2004, British Journal of Cancer.
[39] Economic evaluation of laparoscopic surgery for colorectal cancer , 2007, International Journal of Technology Assessment in Health Care.
[40] D. Nowlan,et al. Costs and benefits. , 1980, Irish medical journal.
[41] N. Bansback,et al. A rapid and systematic review of the evidence for the clinical effectiveness and cost-effectiveness of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer. , 2002, Health technology assessment.
[42] D. Cunningham,et al. Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer , 2002, British Journal of Cancer.
[43] R. Stephens,et al. Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer , 2002, British Journal of Cancer.
[44] D. Whynes,et al. Filtering Strategies in Mass Population Screening for Colorectal Cancer , 1992, Medical decision making : an international journal of the Society for Medical Decision Making.
[45] D. Whynes,et al. The cost of screening for colorectal cancer. , 1991, Journal of epidemiology and community health.
[46] N. Freemantle,et al. Cost-effectiveness of combination chemotherapy (oxaliplatin or irinotecan in combination with 5-FU/FA) compared with 5-FU/FA alone , 2001 .
[47] T. Hickish,et al. Irinotecan in second-line treatment of metastatic colorectal cancer: improved survival and cost-effect compared with infusional 5-FU. , 1999, European journal of cancer.
[48] D. Whynes,et al. Faecal occult blood screening for colorectal cancer: is it cost-effective? , 1998, Health economics.
[49] D. Cunningham,et al. Mature results from three large controlled studies with raltitrexed ('Tomudex'). , 1998, British Journal of Cancer.
[50] J. Brown,et al. Cost of quality management and information provision for screening: colorectal cancer screening , 2000, Journal of medical screening.
[51] D. Cunningham,et al. Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment , 2007, British Journal of Cancer.